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Dear  Editor,  
We   read  with  great   interest   the  article   reporting   the   results   of   the  CONFIDent   trial  
which   aimed   to   assess   the   short-­term   efficacy   of   PTNS   against   sham   electrical  
stimulation   in  adults  with   faecal   incontinence  (FI).1  The  authors  should  certainly  be  
congratulated  for  completing  the  study  since  surgical  trials  are  notoriously  difficult  to  
implement   but   we   would   like   to   comment   on   its   conclusions   in   view   of   our   great  
experience  administrating  the  therapy  and  treating  such  patients.2,3  
The  authors  conclude   that  PTNS  did  not  confer  any  significant  clinical  benefit  after  
12  weeks  because  the  primary  outcome  (i.e.  50%  reduction   in  weekly   incontinence  
episodes)  was  not   found   to  be  statistically  different  between  PTNS   (38%  achieved  
the  primary  outcome)  and  sham  (31%)  patients.  Firstly,   it   is  debatable  whether   the  
selection  of  this  outcome  is  an  appropriate  metric  to  quantify  symptom  improvements  
particularly  after  a  very  short  period  of  three  months  when  patients  had  symptoms  for  
48-­60  months.  We  do  wonder  whether  physicians  in  other  specialties  would  render  a  
treatment   ineffective   if   a  50%   reduction,   in   cholesterol   levels   for  example,  was  not  
achieved  within   a   few  weeks.   Interestingly,   the   25%,   75%   and   100%   reduction   in  
incontinence   episodes   all   showed   a   trend   favouring   PTNS,   albeit   not   statistically  
significant.  Despite  the  (in)appropriateness  of  the  chosen  primary  outcome,  it  is  can  
be  argued   that   if   the   treatment  was  administered   for   a   longer   time  period  or   even  
with  different  neurostimulation  parameters,  dependent  on  patients  nerve  conduction  
characteristics,  the  result  might  have  different.    
The   authors   also   reported   that   the   mean   number   of   incontinence   episodes  
significantly   decreased   in   the   PTNS   group   (2.26,   95%   CI   4.19   to   0.34,   p=0.02)  
although  their  group  consisted  of  a  large  number  of  patients  with  passive  FI  for  which  
bulking   agents   might   be   more   appropriate.   It   is   interesting   that   the   results   of  
anorectal   physiology,   a   standard   test   performed   in   all   patients,   are   not   given   and,  
hence,   we   do   not   know   whether   the   two   groups   are   truly   matched   at   baseline  
physiological   characteristics.   Furthermore,   a   significant   reduction   in   the   mean  
number   of   urge   incontinence   episodes   was   noted   (1.46,   95%   CI   2.69   to.0.22,  
p=0.02)  and  accompanied  by  reduction  in  the  use  of  loperamide  (29%  PTNS  patients  
reduced  their  loperamide  intake  vs  11%  sham  patients)  and,  more  importantly,  by  a  
significant   improvement   in  patient-­reported  outcomes  yet   the  authors  conclude   that  
the  improved  symptoms  “might  or  might  not  be  helpful  to  patients”.  FI  treatments  aim  
to  control   symptoms   rather   than  cure   them  with   the  aim   to   improve   their  quality  of  
life,  reducing  social  isolation  and  allowing  patients  to  achieve  some  form  of  normality  
pursuing  their  activities  of  daily  living.  This  probably  explains  why  all  domains  of  the  
Rockwood   Faecal   Incontinence   Questionnaire   and   the   SF-­36   scores   appeared   to  
improve  in  the  PTNS  group  but  not  in  patients  that  received  sham  stimulation.    
In   conclusion,   this   study   has   confirmed   the   findings   of   previous   large   prospective  
studies   with   longer   follow-­up2   that   PTNS   has   an   excellent   safety   profile,   which   is  
well-­tolerated  by  patients   resulting   in   improved  symptoms  and  quality  of   life  scores  
even  in  the  short-­term.3,4  The  real  question  is  not  whether  there   is  a  placebo  effect  
but  whether  careful  patient  selection,  modification  of  the  initial  treatment  protocol,  or  
of  the  neurostimulation  parameters  and  the  frequency  of  maintenance  sessions  can  
result   in   even   greater   improvements.   We   are   concerned   that   the   findings   of   this  
study  may  be  interpreted  incorrectly  by  the  National  Institute  of  Clinical  Excellence  in  
the   United   Kingdom   to   deny   patients   a   potentially   excellent   treatment,   particularly  
since   all   other   current   FI   treatments   commit   patients   to   complex   and   invasive  
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